{"schema_version":"secwatch.filing_event.v1","accession":"0001396814-23-000077","form_type":"8-K","ticker":"PCRX","cik":"0001396814","company_name":"Pacira BioSciences, Inc.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.859736+00:00","generated_at":"2026-06-08T23:47:11.620529+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Pacira Q3 net income $10.9M, cuts FY EXPAREL guidance; CEO Stack to retire","bullets":["Total revenues $163.9M, down ~2% YoY; EXPAREL sales $128.7M, down from $132.6M.","GAAP net income $10.9M ($0.23/sh) vs net loss $0.7M in Q3 2022; adjusted EBITDA $52.9M.","Lowers FY 2023 EXPAREL net product sales guidance to $535-540M from prior $550-560M.","CEO Dave Stack will retire; remains until successor appointed, then consulting through Aug 2025.","PDUFA action date for EXPAREL lower extremity nerve block on track for Nov 13, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001396814-23-000077","json":"https://secwatch.observer/filing/0001396814-23-000077.json","markdown":"https://secwatch.observer/filing/0001396814-23-000077.md","text":"https://secwatch.observer/filing/0001396814-23-000077.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1396814/000139681423000077/0001396814-23-000077-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1396814/000139681423000077/pcrx-20231102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T23:47:11.620529+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0d82592680c715d2970811d360e5cb371448300d","claim":"Pacira BioSciences, Inc. reported financial results for third quarter of 2023.","evidence_excerpt":"Total revenues were $163.9 million in the third quarter of 2023, versus $167.5 million reported for the third quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1396814/000139681423000077/0001396814-23-000077-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter of 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"0d82592680c715d2970811d360e5cb371448300d","claim":"Pacira BioSciences, Inc. reported financial results for third quarter of 2023.","evidence_excerpt":"GAAP net income was $10.9 million, or $0.23 per share (basic and diluted) in the third quarter of 2023, compared to a net loss of $0.7 million, or $(0.02) per share (basic and diluted) in the third quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1396814/000139681423000077/0001396814-23-000077-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter of 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"c97f4c27bc915076dc3140a11bc47d2c03629b5f","claim":"Pacira BioSciences, Inc. reported full-year 2023 results: revenue EXPAREL net product sales of $535 million to $540 million. Guidance lowered.","evidence_excerpt":"Pacira now expects full-year EXPAREL net product sales of $535 million to $540 million versus the company's previously guided range of $550 million to $560 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1396814/000139681423000077/0001396814-23-000077-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full-year 2023"},{"label":"Revenue","value":"EXPAREL net product sales of $535 million to $540 million"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}